Search results for: Maria Lowe
Filter search results
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
12 January 2013
This paper counters the recently-published recommendation by Claxton et al[1] that NICE should lower its cost-per-QALY threshold from the current £20,000–£30,000 official range to £12,936. The Claxton et al paper…
Cholesterol and Coronary Heart Disease: Consensus or Controversy?
1 March 1991
…considerable. It is also necessary to define any risks involved, and whether they relate to having a low cholesterol, lowering a raised cholesterol, or how that lowering is achieved. This…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…developed such as incubator laboratories, training and recruitment of local experts in patent law, and provision of business development planning and other services. Public money and lower-risk bank finance have…
Dementia: The R&D Landscape
1 November 2015
…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
…being lower. The value at which prices are currently set in a single-price system will impact on the consequences of a move to a multiple-price system. A number of US…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…and development (R&D) cost of an orphan drug is around the 27% of the cost of a non-orphan. However, potential market revenue is also lower for orphan drugs compared to…
Unrelieved Pain in Palliative Care in England
1 September 2019
…their lowest since palliative care is excellent in hospices, there would still be 50,709 palliative care patients dying in some level of pain each year. Of these patients, 5,298 would…
Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
11 July 2023
…and medicine research and development (R&D) is significantly lower in comparison to other diseases such as cancer. However, recent breakthroughs and growing R&D pipeline show that this area has high…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…does not account for rebates and discounts that are applied in practice and net spend is likely to be much lower for many products on this list, given the significant…